Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747
AQC
0.015
200%
BMO
0.001
-50%
YRL
0.18
102.2%
BOT
0.155
-50%
PFE
0.023
91.7%
IPB
0.005
-44.4%
FAL
0.375
87.5%
CDE
0.023
-39.5%
LKO
1.38
84%
BMG
0.007
-36.4%
ICR
0.014
75%
LIC
4.57
-35.1%
ATH
0.015
66.7%
AKN
0.004
-33.3%
QXR
0.005
66.7%
ECT
0.002
-33.3%
RMI
0.02
66.7%
PNT
0.01
-33.3%
WR1
0.23
58.6%
LOC
0.13
-25.7%
NGY
0.031
55%
BLZ
0.003
-25%
ALR
0.003
50%
GTR
0.003
-25%
AUK
0.003
50%
UNT
0.006
-25%
JAY
0.003
50%
URF
0.32
-22.9%
KCC
0.06
50%
W2V
0.007
-22.2%
SFM
0.21
50%
CPO
0.011
-21.4%
DY6
0.3
46.3%
SKM
0.19
-20.8%
IBX
0.016
45.5%
OLY
0.12
-20%
PGY
0.013
44.4%
ORD
0.32
-20%
RDG
0.01
42.9%
HMX
0.029
-19.4%
